Portfolio news:

Series A‑Runde bei TGFS-Portfoliounternehmen Altavo GmbH aus Dresden

TGFS

21 February 2024

Altavo GmbH, an AI-based voice rehabilitation startup founded in 2021, has successfully closed its Series A financing round. A European consortium led by OCCIDENT invests M€ 5 in the development of Altavo’s innovative Artificial Voice Technology. TGFS has been supporting the company since 2021.

In addition to the lead investor, Novalis Biotech, bm‑t beteiligungsmanagement thüringen GmbH and others are also participating. Nearly all seed investors from the initial funding round in December 2021 are also participating, including TGFS, HTGF | High-Tech Gründerfonds, Saxonia Systems Holding GmbH and TUDAG TU Dresden Aktiengesellschaft.

Rudolf von Buenau, Managing Director and co-founder of Altavo, stated: “We are delighted to have secured a strong group of European investors for our vision of giving voiceless people their voice back.” Altavo’s Artificial Voice is a medical device designed to restore a person’s natural-sounding voice, for example following a laryngectomy or during mechanical ventilation. Developed in collaboration with the Technical University of Dresden, the proprietary “Silent Speech” technology relies on non-invasive radar sensor and cutting-edge neural network architectures. The Series A funding will support further company growth, product development, clinical trials for regulatory approval, and international expansion.

Michael Thiele, Investment Manager, bm|t, and Soeren Schuster, Managing Director TGFS, as regional partners on the deal, commented: “With its locations in Dresden and Jena, Altavo is a prime example of the innovative strength of the Central German region and the successful collaboration between start-ups and universities. We are delighted to invest in this a promising med-tech company that benefits from and enhances the existing infrastructures at both sites.”

Your contact person
Sören Schuster | Managing Director TGFS
M +49 172 2001097
soeren.schuster@cfh.de

TGFS deal team
Marie Grund, Jan Thomas Alter and Oliver Latz